{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.1","spread":"12.1","upperLimit":"14.9","value":"13.6"},{"groupId":"OG001","lowerLimit":"10.4","spread":"10.4","upperLimit":"13.9","value":"12.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"478"},{"groupId":"OG001","value":"476"}],"units":"Participants"}],"description":"OS was defined as the duration from the date of randomization until the date of death from any cause. Participants who were lost to follow-up were censored at the last date the participant was known to be alive, and participants who remained alive were censored at the time of data cutoff.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received lenvatinib capsules 12 mg based on the participant's body weight \\>=60 kg or 8 mg based on the participant's body weight \\<60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.","id":"OG000","title":"Lenvatinib"},{"description":"Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.","id":"OG001","title":"Sorafenib"}],"paramType":"MEDIAN","populationDescription":"The FAS included all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"From date of randomization until date of death from any cause (approximately up to 3.8 years)","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}